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1. INTRODUCTION {#ccr32665-sec-0001}
===============

Sarcoidosis is a granulomatous disorder of unknown origin that can affect multiple organ systems. Most commonly, it affects the lungs, skin, and lymphatic system. It typically presents in young adults. Central nervous system (CNS) involvement occurs in only 5%‐10% of cases and increases morbidity and mortality significantly.[1](#ccr32665-bib-0001){ref-type="ref"} The most common neurologic finding in neurosarcoidosis is cranial neuropathies, predominantly peripheral facial palsy (occurring in 50% of patients), and optic neuritis followed by palate dysfunction, hearing abnormalities, and vertigo.[2](#ccr32665-bib-0002){ref-type="ref"}, [3](#ccr32665-bib-0003){ref-type="ref"}, [4](#ccr32665-bib-0004){ref-type="ref"} Other manifestations include hypothalamic and pituitary abnormalities, chronic aseptic meningitis, mass‐lesion effect, and seizures.[1](#ccr32665-bib-0001){ref-type="ref"} Hydrocephalus occurs in only 6% of cases of neurosarcoidosis, but of all manifestations of CNS involvement, it has been reported to confer the worst long‐term prognosis.[5](#ccr32665-bib-0005){ref-type="ref"}, [6](#ccr32665-bib-0006){ref-type="ref"}, [7](#ccr32665-bib-0007){ref-type="ref"}

In most reported cases of neurosarcoidosis with hydrocephalus, the patient had a previous diagnosis of systemic sarcoidosis. Hydrocephalus as the presenting symptom of sarcoidosis in a previously healthy patient is an atypical presentation that is exceedingly rare and challenging to diagnose.[1](#ccr32665-bib-0001){ref-type="ref"}, [6](#ccr32665-bib-0006){ref-type="ref"} We present the case of a previously healthy 52‐year‐old woman with significant hydrocephalus of all four ventricles as the presenting manifestation of sarcoidosis.

2. CASE PRESENTATION {#ccr32665-sec-0002}
====================

A 53‐year‐old African‐American woman with no past medical history visited the emergency department due to progressive nausea and vomiting. She had a month‐long course of fatigue, headaches, intermittent vertigo, tinnitus, and ataxia. Review of systems revealed she had an unintentional weight loss of 30 pounds over the last 4 months. Neurologic examination showed right gaze‐evoked nystagmus, postural instability, and an unsteady shuffling gait. Fundoscopic examination showed no papilledema or other abnormalities. Respiratory examination was normal. Her complete blood count and routine biochemistry were normal. C‐reactive protein and erythrocyte sedimentation rate (ESR) were within normal limits. Serum level of angiotensin‐converting enzyme (ACE) was 51 U/L (normal range: 12‐60 U/L). Brain computed tomography (CT) revealed remarkable hydrocephalus with dilation of all four ventricles. Magnetic resonance imaging (MRI) showed patency of the cerebral aqueduct and ruled out cerebral or subarachnoid mass lesions, consistent with communicating hydrocephalus (Figure [1](#ccr32665-fig-0001){ref-type="fig"}). Lumbar puncture was performed in light of clinical and radiographic findings. Cerebrospinal fluid (CSF) was transparent and showed lymphodominant pleocytosis with increased protein level (104 mg/dL), markedly decreased glucose (21 mg/dL), and normal opening pressure. Chest CT showed bilateral lymphadenopathy, and biopsy revealed noncaseating granulomas admixed with giant cells without evidence of malignancy or infection (Figure [2](#ccr32665-fig-0002){ref-type="fig"}). A diagnosis of neurosarcoidosis with hydrocephalus was made, and the patient was started on 1 g of intravenous solumedrol for 5 days with a subsequent oral prednisone taper with methotrexate. Three months later, she received a ventricular shunt for persistent severe gait disturbance. She returned to walking independently within one month of the procedure and has since shown marked improvement in all neurologic symptoms.

![Dilation of third and lateral ventricles with FLAIR sequence (A, B). Enlargement of the third and fourth ventricles with patent cerebral aqueduct on T1 sagittal sequence (C)](CCR3-8-363-g001){#ccr32665-fig-0001}

![Chest CT demonstrating bilateral enlarged thoracic lymph nodes of 13.0 X 25.3 mm and 9.6 X 14.5 mm consistent with sarcoidosis (A, B). Lymph node biopsy demonstrating granulomatous inflammatory reaction with multinucleate giant cells (black arrowhead) and fibrosis (white arrowhead) (C)](CCR3-8-363-g002){#ccr32665-fig-0002}

3. DISCUSSION {#ccr32665-sec-0003}
=============

Hydrocephalus is a very rare complication of sarcoidosis, especially as the presenting symptom.[6](#ccr32665-bib-0006){ref-type="ref"} We present one such case in this report. To the best of our knowledge, only 21 others exist in the literature, of which we were able to include 19 in this report (Table [1](#ccr32665-tbl-0001){ref-type="table"}).[7](#ccr32665-bib-0007){ref-type="ref"}, [8](#ccr32665-bib-0008){ref-type="ref"}, [9](#ccr32665-bib-0009){ref-type="ref"}, [10](#ccr32665-bib-0010){ref-type="ref"}, [11](#ccr32665-bib-0011){ref-type="ref"}, [12](#ccr32665-bib-0012){ref-type="ref"}, [13](#ccr32665-bib-0013){ref-type="ref"}, [14](#ccr32665-bib-0014){ref-type="ref"}, [15](#ccr32665-bib-0015){ref-type="ref"}, [16](#ccr32665-bib-0016){ref-type="ref"}, [17](#ccr32665-bib-0017){ref-type="ref"}, [18](#ccr32665-bib-0018){ref-type="ref"}, [19](#ccr32665-bib-0019){ref-type="ref"}, [20](#ccr32665-bib-0020){ref-type="ref"}, [21](#ccr32665-bib-0021){ref-type="ref"}, [22](#ccr32665-bib-0022){ref-type="ref"} Hydrocephalus typically presents with nonspecific symptoms, and the diagnosis is made based on imaging.[8](#ccr32665-bib-0008){ref-type="ref"} The differential diagnosis is extensive (Table [2](#ccr32665-tbl-0002){ref-type="table"}) making the correct attribution difficult due to a lack of definitive diagnostic testing for neurosarcoidosis. As such, a high degree of clinical suspicion must be maintained.

###### 

Hydrocephalus as the presenting symptom in systemic sarcoidosis cases reported in the literature, including the current case

  Author                                                   ESR/CRP                      Serum ACE   CSF Findings                                                                                 Diagnosis                                                                                         Type               Treatment                                                                             Outcome
  -------------------------------------------------------- ---------------------------- ----------- -------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------- ------------------ ------------------------------------------------------------------------------------- ---------------------------------
  This report                                              ESR: Normal, CRP: Normal     Normal      Lymphodominant pleocytosis, elevated protein, hypoglycorrhachia                              Lymphadenopathy on chest CT                                                                       Communicating      Corticosteroids + methotrexate, followed by VP months later                           Partial recovery
  Brouwer 2009[9](#ccr32665-bib-0009){ref-type="ref"}                                   Normal      Lymphodominant pleocytosis, elevated protein                                                 Lymphadenopathy on FDG‐PET                                                                        Communicating      Corticosteroids                                                                       Complete recovery
  Muayqil 2006[16](#ccr32665-bib-0016){ref-type="ref"}     ESR: Normal                              Lymphodominant pleocytosis                                                                   Lymphadenopathy on CXR and chest CT; meningeal and hypothalamic enhancement in brain MRI          Communicating      VP shunt + corticosteroids                                                            Partial recovery
  Muniesa 2006[17](#ccr32665-bib-0017){ref-type="ref"}                                  Elevated    Leukocytic pleocytosis                                                                       Cutaneous lesions                                                                                 Communicating      VP shunt + corticosteroids                                                            Complete recovery
  Onoda 2004                                                                                        Lymphodominant pleocytosis, elevated protein, hypoglycorrhachia                              Increased ACE in CSF                                                                              Communicating      VP shunt + corticosteroids                                                            Died from nosocomial pneumonia
  Sano 2015[18](#ccr32665-bib-0018){ref-type="ref"}                                                 Lymphodominant pleocytosis, protein elevated protein, hypoglycorrhachia, ACE normal          Lymphadenopathy on chest CT; meningeal lesions in basal cisterns                                  Communicating      VP shunt + corticosteroids +Methotrexate + Infliximab                                 Partial recovery
  Sugiyama 2016[19](#ccr32665-bib-0019){ref-type="ref"}    ESR: Elevated, CRP: Normal   Normal      Leukocytic pleocytosis, elevated protein                                                     Lymphadenopathy on whole body contrast CT and FDG‐PET                                             Communicating      VP shunt + corticosteroids                                                            Partial recovery
  Zoja 2012[21](#ccr32665-bib-0021){ref-type="ref"}                                                                                                                                              Autopsy                                                                                           Communicating                                                                                            Death
  Benzagmout 2007[8](#ccr32665-bib-0008){ref-type="ref"}                                Elevated    Elevated opening pressure, lymphodominant pleocytosis, elevated protein, hypoglycorrhachia   Cervical and submandibular lymphadenopathy                                                        Noncommunicating   External Ventricular Drain + Corticosteroids                                          Partial recovery
  Berhouma 2009[23](#ccr32665-bib-0023){ref-type="ref"}                                                                                                                                          Brain MRI with temporal trapped horn and multiple enhancing lesions in subarachnoid space         Noncommunicating   Right temporal tip lobectomy + corticosteroids                                        Complete recovery
  Brouwer 2009[9](#ccr32665-bib-0009){ref-type="ref"}                                   Normal      Lymphodominant pleocytosis, elevated protein                                                 Lymphadenopathy on FDG‐PET                                                                        Noncommunicating   Ventriculoscopy assisted fenestration of lateral ventricle cyst                       Complete recovery
  Chandna 2015[10](#ccr32665-bib-0010){ref-type="ref"}                                  Normal                                                                                                   Lymphadenopathy on CXR                                                                            Noncommunicating   VP shunt + corticosteroids                                                            Death
  Chiang 2002[11](#ccr32665-bib-0011){ref-type="ref"}                                   Elevated                                                                                                 Cutaneous lesions                                                                                 Noncommunicating   VP shunt + corticosteroids                                                             
  Hitti 2015[12](#ccr32665-bib-0012){ref-type="ref"}                                                Normal                                                                                       Leptomeningeal enhancement in brain and spine MRI months later                                    Noncommunicating   VP shunt + corticosteroids +Mycophenolate mofetil                                      
  Kim 2012[13](#ccr32665-bib-0013){ref-type="ref"}                                                  Leukocytic pleocytosis, elevated protein                                                     Lymphadenopathy on CXR                                                                            Noncommunicating   VP shunt + corticosteroids                                                            Complete recovery
  Matsuda 2015[14](#ccr32665-bib-0014){ref-type="ref"}                                  Normal      Lymphodominant pleocytosis, hypoglycorrhachia                                                Neuroendoscopic biopsy of enhancing ventricular lesions                                           Noncommunicating   Ventriculostomy, followed by VP shunt + corticosteroids                               Complete recovery
  McKeever 2019[15](#ccr32665-bib-0015){ref-type="ref"}                                                                                                                                          Nodular lesions in brain MRI years later                                                          Noncommunicating   Endoscopic third ventriculostomy, years later recurred and required shunt             Complete recovery first episode
  Tabuchi 2013[24](#ccr32665-bib-0024){ref-type="ref"}     ESR: Elevated, CRP: Normal   Normal      Pleocytosis, elevated protein                                                                Lymphadenopathy on CXR                                                                            Noncommunicating   VP shunt + corticosteroids                                                            Partial recovery
  Westhout 2008[20](#ccr32665-bib-0020){ref-type="ref"}    ESR: Elevated                            Elevated protein                                                                             Biopsy of temporal lobe lesion                                                                    Noncommunicating   VP shunt + corticosteroids                                                            Complete recovery
  Yoshitomi 2015[25](#ccr32665-bib-0025){ref-type="ref"}   CRP: Elevated                            Elevated opening pressure, hypoglycorrhachia                                                 Diffuse leptomeningeal enhancement in brain MRI and mass lesions in third and fourth ventricles   Noncommunicating   Endoscopic fenestration foramen of Magendie, followed by VP shunt + corticosteroids   Complete recovery
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###### 

Differential diagnosis of acquired hydrocephalus in adults

  -------------------------------------------------------
  Subarachnoid/Intraventricular Hemorrhage
  Trauma
  Tumor and metastases (including of the leptomeninges)
  Meningitis/encephalitis
  Bacterial (including syphilis)
  Viral (including EBV and HIV)
  Fungal
  Infectious etiologies
  Tuberculosis
  Lyme disease
  Toxoplasmosis
  Neurocysticercosis
  Whipple\'s disease
  Inflammatory etiologies
  Sarcoidosis
  Systemic lupus erythematosus (SLE)
  Behçet\'s disease
  Wegner\'s granulomatosis
  -------------------------------------------------------
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Hydrocephalus secondary to sarcoidosis can present as communicating or noncommunicating. The latter scenario is the most common (60% of cases included in this report), and the presence of mass lesions in the CNS can raise the possibility of the diagnosis and even provide a site for biopsy. In the case of communicating hydrocephalus, when the differential diagnosis includes infectious or neoplastic pathologies of the leptomeninges, additional studies (including CSF analysis and chest imaging) usually provide the clues for diagnosis. In 50% of the patients, the diagnosis was suspected when lymphadenopathy was found, most commonly in chest imaging. Among patients with communicating hydrocephalus, this was the most common way to make the diagnosis (63%), including in our patient. In two of those patients, there were also abnormal findings in the contrast MRI (Table [1](#ccr32665-tbl-0001){ref-type="table"}). In one patient, the diagnosis was made by biopsy of cutaneous lesions, in another, it was suggested by elevated ACE levels in CSF, and in the last case, the patient died suddenly from acute hydrocephalus and the diagnosis was made by pathological examination of the leptomeninges at autopsy.

Serum ACE levels were only reported in half of patients, with only 30% being elevated (25% of communicating and 33% of noncommunicating). All patients with communicating hydrocephalus in whom ESR was reported had normal values, while it was elevated in both patients with noncommunicating pathology in which it was reported. The most common abnormalities reported in CSF analysis include pleocytosis (100% of communicating and 63% of noncommunicating hydrocephalus) with a lymphocytic predominance in 75% of cases, and elevated protein (71% and 75% respectively). While the number of patients reported is low, the above findings suggest that serum ACE levels have limited sensitivity, but the specificity of the test might still make it valuable. Sarcoidosis should be a diagnostic consideration in patients with hydrocephalus with CSF pleocytosis or elevated protein levels in whom microbiological and cytology studies are negative.

While there has been no controlled trial for medical treatment of neurosarcoidosis, the consensus remains that corticosteroid therapy is first‐line. Ventriculoperitoneal (VP) shunt placement should be considered for symptomatic hydrocephalus.[8](#ccr32665-bib-0008){ref-type="ref"} Of the cases reported in the literature, only one case of communicating hydrocephalus in neurosarcoidosis was successfully treated with corticosteroids alone, all other cases required surgical management (VP shunt, ventriculostomy, or ventricle fenestration) which in many cases took place before a definite diagnosis in order to manage the hydrocephalus. In the present case, VP shunt placement was done after three months of persistent and severe gait disturbance despite corticosteroid treatment, with rapid improvement in neurologic symptoms. Obviously, in cases of acute hydrocephalus, ventriculostomy can be life‐saving.

While most published reports of hydrocephalus in the context of sarcoidosis suggest a mortality rate as high as 75%, the great majority of those cases happened in patients with widespread disease that had not responded to treatment.[6](#ccr32665-bib-0006){ref-type="ref"}, [8](#ccr32665-bib-0008){ref-type="ref"}, [26](#ccr32665-bib-0026){ref-type="ref"} In the current series of patients presenting with hydrocephalus, the reported mortality is 15%, with one patient dying suddenly from acute hydrocephalus, another from pulmonary embolism, and the last one from nosocomial pneumonia. The rest of the patients in whom outcomes were reported had either partial (35%) or complete (50%) recovery with treatment. Nevertheless, long‐term prognosis seems to depend more on the response of the underlying sarcoidosis to immunosuppressant treatment rather than the presence of hydrocephalus.

4. CONCLUSION {#ccr32665-sec-0004}
=============

We present a rare case of neurosarcoidosis manifesting as subacute communicating hydrocephalus in a previously healthy patient. Though this pathology may pose a diagnostic challenge, it responds well to treatment and prognosis is favorable.
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